 The primary parameters recorded by the registry comprise details of each patients clinical status, including any coexisting or underlying conditions, and the type, dose, duration and outcome during the first 3 months of therapy of antithrombotic treatment. Study endpoints are clinically recognized and objectively confirmed recurrences of VTE, major and minor bleeding complications, and death. 